Trial · NCT04856917
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Facial Inflammatory Lesion Counts at Week 12 | Baseline, Week 12 | Participants in ITT Analysis Set with available data were analyzed. | lesions | MEAN |
| SECONDARY | Change From Baseline in Facial Inflammatory Lesion Counts at Weeks 2, 4, 8, and 20 | Baseline, Weeks 2, 4, 8, and 20 | Participants in the ITT Analysis Set with available data were analyzed. | lesions | MEAN |
| SECONDARY | Percent Change From Baseline in Facial Inflammatory Lesion Counts at Weeks 2, 4, 8, 12, and 20 | Baseline, Weeks 2, 4, 8, 12 and 20 | Participants in the ITT Analysis Set with available data were analyzed. | percent change | MEAN |
| SECONDARY | Change From Baseline in Facial Non-inflammatory Lesion Counts at Weeks 2, 4, 8, 12, and 20 | Baseline, Weeks 2, 4, 8, 12, and 20 | Participants in the ITT Analysis Set with available data were analyzed. | lesions | MEAN |
| SECONDARY | Percent Change From Baseline in Facial Non-Inflammatory Lesion Counts at Weeks 2, 4, 8, 12, and 20 | Baseline, Weeks 2, 4, 8, 12, and 20 | Participants in the ITT Analysis Set with available data were analyzed. | percent change | MEAN |
| SECONDARY | Change From Baseline in Total Facial Lesion (Inflammatory and Non-inflammatory Lesions) Counts at Weeks 2, 4, 8, 12, and 20 | Baseline, Weeks 2, 4, 8, 12, and 20 | Participants in the ITT Analysis Set with available data were analyzed. | lesions | MEAN |
| SECONDARY | Percent Change From Baseline in Total Facial Lesion (Inflammatory and Non-inflammatory Lesions) Counts at Weeks 2, 4, 8, 12, and 20 | Baseline, Weeks 2, 4, 8, 12, and 20 | Participants in the ITT Analysis Set with available data were analyzed. | percent change | MEAN |
| SECONDARY | Change From Baseline in Facial Investigator's Global Assessment (IGA) at Weeks 2, 4, 8, 12, and 20 | Baseline, Weeks 2, 4, 8, 12, and 20 | Participants in the ITT Analysis Set with available data were analyzed. | units on a scale | MEAN |
| SECONDARY | Percentage of Participants Achieving a Facial IGA of Clear (0) or Almost Clear (1) With at Least a 2-grade Decrease From Baseline at Weeks 2, 4, 8, 12, and 20 | Baseline, Weeks 2, 4, 8, 12, and 20 | Participants in the ITT Analysis Set with available data were analyzed. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants in Each Response Category for the Patient Global Impression of Severity (PGI-S) at Weeks 2, 4, 8, 12, and 20 | Baseline, Weeks 2, 4, 8, 12, and 20 | Participants in the ITT Analysis Set with available data were analyzed. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants in Each Response Category for the Patient Global Impression of Change (PGI-C) at Weeks 2, 4, 8, 12, and 20 | Baseline, Weeks 2, 4, 8, 12, and 20 | Participants in the ITT Analysis Set with available data were analyzed. | percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in Dermatology Life Quality Index Questionnaire (DLQI) Total Score at Weeks 2, 4, 8, 12, and 20 | Baseline, Weeks 2, 4, 8, 12, and 20 | Participants in the ITT Analysis Set with available data were analyzed. | units on a scale | MEAN |
| SECONDARY | Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score at Weeks 2, 4, 8, 12, and 20 | Baseline, Weeks 2, 4, 8, 12, and 20 | Participants in the ITT Analysis Set with available data were analyzed. | units on a scale | MEAN |
| SECONDARY | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | First dose of study drug until end of study (up to 20 weeks) | Safety Analysis Set. | participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04856917/outcomes